Pyrophyte Acquisition Corp.

This filing directly recalibrates the trust distribution floor and public share count ahead of the newly established April 29, 2027 deadline. Investors tracking redemption windows will note the $12.93 per-share payout and the $18.3 million residual trust balance, which defines the maximum recoverable amount if dissolution occurs before a deal closes. The reduction of 100,100 shares lowers the outstanding public float to 6,445,104 shares, altering relative voting weight and future dilution exposure. The contractual requirement for $100,000 monthly sponsor contributions extends the trust’s liquidity runway and financially commits the sponsor to preserving liquidation value throughout the extension, indicating active continuation of deal pursuit despite the complete absence of any target announcement, revenue projection, or operational milestone. All metrics, dates, and commitments are sourced exclusively from the registrant’s Item 8.01 report.

This filing confirms the Sponsor’s commitment to sustain operations for an additional twelve-month extension cycle using fully subordinated, trust-waived debt, indicating active pursuit of a target rather than imminent liquidation. The $100,000 monthly contribution rate directly offsets trust account erosion from ongoing corporate and administrative expenses, meaning the actual per-share trust value available at redemption will reflect cumulative monthly deductions over the additional year. The compressed May 1 reversal deadline establishes a discrete liquidity event for public investors before the new funding cycle commences. From a capital structure standpoint, the convertible note provision introduces conditional dilution: if the Sponsor elects to convert up to $1,500,000 prior to a business combination, it would inject warrants exercisable at $11.50 per share that carry identical rights to the original private placement warrants but escape their standard forfeiture clauses. The document contains no disclosures regarding target candidates, pipeline meetings, revenue projections, market sizing, operational strategy, or strategic rationale beyond routine governance amendments and financial accommodation terms.

This filing materially shifts the near-term redemption calendar by activating preparations for a Fourth Extension EGM and supplying the precise trust balance (~$19,545,779) and per-share liquidation metric (~$12.91) investors must weigh against the 1,513,954 outstanding public shares when deciding whether to redeem. By documenting that the sponsor funded the previous monthly extension installments at $75,697.70 per month, the filing confirms sponsor conduct and illustrates the cash infusions sustaining the trust pool ahead of the next deadline. No target acquisition, revenue figures, technology disclosures, or partnership announcements are contained in the text; instead, the document relies on standard forward-looking risk disclaimers and designates Chief Financial Officer Sten Gustafson as the contact for obtaining the definitive proxy statement. For investors tracking SPAC mechanics, the substance lies in the verified extension payment trail and the recalculated liquidation floor, which together dictate whether existing positions should be hedged, tendered, or maintained pending the outcome of the fourth extension vote.

The document materially updates the redemption calendar by pinpointing the Fourth Extension EGM as the near-term catalyst where public shareholders can exercise redemption rights against the trust fund. By confirming the sponsor fully satisfied its $75,697.70 monthly payment schedule, the filing serves as a compliance checkpoint regarding sponsor capital contributions during the extension phase. For investors monitoring trust value and capital preservation, the reported $19,545,779 balance and the Company’s stated $12.91 per-share approximation establish the theoretical redemption floor tied to the upcoming vote, though the Company explicitly frames this figure as contingent on proper submission for redemption at the Fourth Extension EGM and subject to proxy approval. The mailing of the definitive proxy statement initiates the formal voting window, requiring holders to review the extension proposal, associated risks, and participant interests before the April 29, 2026, contractual deadline expires.

The deposit clears the final cash call for the Third Extension (which runs through April 29, 2026), confirming the trust remains funded and preventing an automatic termination or forced redemption event at that boundary. By distributing the Fourth Extension proxy materials, the Company has shifted the immediate timeline for investors: shareholders must now determine how to act on the forthcoming vote to prolong the combination window further. No separate business development, partnership, revenue milestone, or litigation update is contained in this filing beyond routine forward-looking cautionary language and the attestation by Chief Financial Officer Sten Gustafson.

The Company’s continued payment of monthly extension fees and active solicitation of a Fourth Extension indicate that management has not yet finalized an initial business combination within the third year of operations. This filing dictates the near-term mechanics for redemption deadlines: the upcoming shareholder vote will establish the new termination date, thereby resetting or closing the window for public shareholders to exercise redemption rights before liquidation triggers. The Company cautions that shareholder approval is uncertain, identifies directors and officers as potential participants in the proxy solicitation, and cross-references risk disclosures in the 10-K for the fiscal year ended December 31, 2024, and the referenced Extension Proxy Statement. No financial performance, customer, or target-related metrics are reported.

By anchoring the monthly extension fee to a $75,000 floor alongside the $0.05 variable rate, the board has structurally altered redemption economics to limit dilution exposure if substantial outflows occur, while keeping the aggregate liability ceiling nearly identical to prior disclosures ($908,376 versus $908,372.40). Chairman Bernard J. Duroc-Danner confirmed these updated financing mechanics directly shift the cost-benefit calculus of the extension vote. The strict 45-day deposit requirement and immediate forfeiture provisions introduce acute timeline pressure ahead of the original April 29, 2026 expiration. Investors retain the ability to reverse prior votes or redemption requests through Continental Stock Transfer & Trust Company, but the revised capital call terms change the downstream value retention profile for those who accept the extension rather than redeem.

According to the proxy statement, the extension is intended to provide additional time to complete the proposed amalgamation with Sio Silica Corporation, whose Vivian sand extraction project experienced a permit denial from the Manitoba government on February 16, 2024. The filing documents a sequence of six consecutive external and internal deadline adjustments dating back to November 2023, indicating persistent regulatory and procedural execution risk. The Board acknowledges that the estimated $12.69 redemption price trails the Company’s reported Record Date public share closing price of $15.43, while simultaneously warning that the Company’s delisting to the OTC Pink tier in October 2024 creates liquidity constraints that may prevent shareholders from executing market sales at favorable levels. Governance implications are highlighted by the Sponsor’s 76.9% voting majority and formal waiver of liquidation rights for Founder shares, which shields insiders from dissolution costs while preserving equity upside. The filing also details the Sponsor’s financial role beyond extensions, including $3,188,561 in outstanding convertible note balances and continuing administrative service fees, underscoring the Company’s structural reliance on Sponsor working capital. Additional material considerations flagged by the Company include potential U.S. CFIUS national security review thresholds for its Cayman Islands domicile, prospective 1% federal excise tax applicability upon redemptions, and extensive Passive Foreign Investment Company tax regimes applicable to U.S. holders.

For shareholders monitoring liquidation triggers, sponsor accountability, and capital preservation, sequential quarterly delinquencies spanning three fiscal periods indicate a structural reporting breakdown rather than a temporary bottleneck. When paired with the disclosed risk of potential accounting control deficiencies, the filing raises immediate concerns about the veracity of historical disclosures and the stability of capital references.

This filing dictates the terminal liquidation runway; rejection forces wind-down and Trust Account distribution within ten business days after April 29, 2026, permanently retiring all warrants. The concurrent redemption period allows early capital extraction, which shrinks the residual trust balance available to finance the Sio deal. The sponsor’s $908,376 funding pledge mitigates per-share dilution from expected redemptions, though the resulting debt ranks as subordinate unsecured obligations payable exclusively from non-trust assets upon dissolution. Management’s near-total equity concentration (76.9%) and forfeiture risk heavily incentivize extension approval over liquidation. Additionally, the NYSE suspension and current OTC Pink listing constrain secondary market liquidity, compounding the pricing divergence between exercising redemption versus open-market sales. Historical extension deposits are explicitly recorded as $1.92 million, $1.08 million, and $908,372.40, while current trust valuations and meeting dates remain bracketed as $[•] per the preliminary draft.

The extension preserves the combination pathway through April 2027, delaying the anticipated filing of the Form F-4 Registration Statement, the preliminary proxy statement/prospectus, and the subsequent extraordinary general meeting where public shareholders would receive notice, review materials, and exercise redemption rights. By resetting the hard deadline twelve months out, the parties avoid automatic termination rights if remaining conditions precedent remain unsatisfied. The filing's risk factors and forward-looking statements, authored and submitted by Pyrophyte and Sio, caution that actual results may materially differ due to specific threats including redemptions by Pyrophyte’s public shareholders being greater than expected, failure to secure shareholder approval, inability to list on the New York Stock Exchange, unexpected costs, operational disruption, and diversion of management time and attention. No operating metrics, customer data, revenue figures, or sponsor compensation changes are disclosed in this filing.

For redemption and deal tracking, the key facts are: the deadline to complete an initial business combination is April 29, 2026; the Trust Account was reduced to roughly $18.1 million after the April 2025 redemptions; only about 1.51 million redeemable public shares remained, while the Sponsor held 5,031,250 Class A shares, about 76.9% of the total; the Sponsor is funding monthly extension contributions and can convert up to $1.5 million of working capital loans into warrants; if the Sponsor fails a contribution, the trustee can liquidate the Trust Account; cash outside the Trust Account is negligible, making the Sponsor loans essential. The filing also confirms the pending Sio Silica transaction remains the target, with a stated Sio valuation of $675,000,000 and a PIPE of $20,122,474 for 3,114,258 shares, and that no operating revenues have been generated. The document contains no customer, revenue, or market-size claims about Sio, only that Sio would continue its business operations following the proposed amalgamation.

The transaction recalibrates the redemption and dissolution calendar to April 29, 2026 and verifies ongoing sponsor compliance with the monthly extension funding covenant. Chief Financial Officer Sten Gustafson signed the filing, attesting to the deposit. Beyond these extension mechanics and the documented $75,697.70 cash movement, the filing contains no additional claims regarding target identification, deal progress, customer relationships, revenue streams, market valuations, technology assets, commercial partnerships, pending litigation, or executive personnel shifts. All temporal markers and monetary figures originate exclusively from the submitted text.

Chronic late filings deprive shareholders of the financial and governance transparency required to vote on trust extensions, approve business combinations, or exercise redemption rights tied to net tangible asset thresholds. Each successive delay postpones the proxy cycle necessary to propose extending the acquisition window or to call a shareholder meeting for a de-SPAC transaction.

Routine trust account contributions from the Sponsor directly counteract administrative expense drain, preserving the per-share cash balance available upon eventual redemption or deSPAC transaction. By documenting the October 31, 2025 funding, the Company confirms the Sponsor is meeting the monthly $75,697.70 obligation without default, extending the operational runway and redemption window through the new April 29, 2026 cutoff rather than face automatic dissolution.

The confirmed deposit signals sponsor compliance with contractual extension-funding covenants, which preserves the trust corpus and defers any mandatory liquidation or shareholder redemption window to the newly set April 29, 2026 cutoff. The 8-K does not update the per-share trust value or identify a transaction target, but it provides verifiable evidence that the SEARCHING mandate remains actively funded. The submission was executed and certified by Chief Financial Officer Sten Gustafson on September 12, 2025.

Repeated reporting delays for a SPAC operating under SEARCHING status typically indicate administrative or internal control gaps at the sponsor or trustee level, which can invite regulatory inquiry and complicate shareholder notifications leading up to a default redemption date. The Chief Financial Officer and Director, Sten Gustafson, explicitly warned that the internal reconciliation process may identify errors or control deficiencies in the Company's accounting practices, creating compliance uncertainty without mechanically shifting the trust distribution schedule or merger timeline.

The monthly funding covenant demonstrates the sponsor is fulfilling its capital preservation obligation to maintain the capital markets vehicle’s active status until the April 29, 2026 termination deadline. Each documented $75,697.70 deposit incrementally supports the trust account balance, which investors track to model redemption floor values and evaluate sponsor skin-in-the-game behavior. Although the filing lacks traditional commercial milestones, it provides verifiable evidence of extension mechanics execution, which is a prerequisite for any future business combination announcement or mandatory redemption trigger.

For investors tracking liquidation timelines, trust balance movements, extension votes, business combination进度, or sponsor behavior, this filing confirms none of those mechanics have changed. However, the disclosed 2023 going-concern caveat and the delayed 2024 Form 10-K indicate the SPAC remains in an extended pre-combination search phase without confirmed resolution of its liquidity assumptions. The auditor transition appears administrative rather than contentious, lowering near-term governance risk, but investors should treat the upcoming 2024 10-K as the next critical inflection point to determine whether management’s going-concern disclosure was remediated prior to any de-SPAC shareholder vote or mandatory dissolution date.

This disclosure confirms the sponsor is actively funding the extension, which directly preserves the trust account balance and legally extends the SPAC's operational and redemption window to April 29, 2026. Investors tracking redemption deadlines and sponsor conduct should monitor these $75,697.70 monthly payments to assess ongoing sponsor commitment and trust value maintenance as the deadline approaches. Beyond the extension mechanics, the filing contains no claims regarding target companies, customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. All statements and figures are attributed to the registrant's own disclosures, signed by Chief Financial Officer Sten Gustafson on July 9, 2025.

This report materially updates the redemption calendar and liquidity timeline for public shareholders, replacing an imminent April 29, 2025 liquidation trigger with a twelve-month extension to April 29, 2026. It documents sponsor conduct by verifying that the sponsor fulfilled its contractual obligation to fund the $75,697.70 monthly extension payment, thereby preserving the trust reserve during the continued search phase. Regarding any other substance, the filing contains zero claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. It provides only standard regulatory metadata, identifying the registrant as a Cayman Islands corporation, listing principal executive offices at 3262 Westheimer Road, Suite 706, Houston, Texas 77098, and classifying the entity as an emerging growth company.

For a SPAC in the searching phase, delayed periodic reporting extends the effective time before sponsors can complete target diligence and circulate updated financials for a shareholder vote, indirectly stretching the pre-merger runway. The admission of unresolved prior-period reporting gaps and the explicit warning of potential accounting control weaknesses raise the probability of restatements or merger delays, which directly influences investor redemption timing assessments and sponsor accountability without altering the trust balance or statutory extension mechanics.

The extension resets the redemption and liquidation calendar exactly one year out, buying time for deal search while structurally altering the company's liquidity profile. The redemption of nearly 4.78 million shares drains a substantial portion of the trust, leaving $18.1 million to fund ongoing operations and likely necessitating additional financing or larger trust replenishments post-combination. The Sponsor's decision to front operational costs through non-recourse, subordinate loans rather than equity indicates a desire to defer dilution and signal confidence, though it increases pre-combination leverage risk. The embedded conversion feature on the working capital facility preserves the Sponsor's ability to inject cheap equity via warrants ($11.50 exercise price) if needed, creating potential future overhang. The mandatory trustee liquidation trigger serves as a critical governance backstop, preventing indefinite stall and guaranteeing an automatic payout mechanism if extension funding commitments lapse.

These amendments directly reshape the shareholder decision matrix for the upcoming April 25, 2025 redemption window. The higher monthly sponsorship rate ($150,000 versus $125,000), larger aggregate ceiling ($1,800,000 versus $1,500,000), and per-share bump ($0.05 versus $0.04) strengthen capital support for a potential initial business combination, while the explicit waiver of the $100,000 dissolution withdrawal preserves additional trust balance for public holders. The tightened 45-day default clause provides an immediate liquidation backstop if funding stalls, reducing extended execution risk. Because shareholders who previously submitted redemption requests may reverse them through Continental Stock Transfer & Trust Company, the amended terms directly influence whether existing redemption pressure accelerates or softens heading into the vote. The restricted investment policy further ensures trust liquidity and safety pending a deal closure or termination.

What changed: A Form 8-K current report classified as a routine compliance exhibit disclosing 'Other Events' under Item 8.01. The filing reports that Pyrophyte Acquisition LLC (the Sponsor) deposited $100,000 into the trust account on June 8, 2026, and another $100,000 on July 20, 2026. These deposits fulfill the monthly extension obligation established at the April 28, 2026 extraordinary general meeting, which extended the deadline to consummate an initial business combination from April 29, 2026 to April 29, 2027. Chief Financial Officer Sten Gustafson attested to these events on August 4, 2026. Why it matters: Mechanically, the dual deposits confirm the sponsor's adherence to the $100,000 monthly funding schedule, directly increasing the trust balance to support the per-share redemption price while halting the liquidation countdown until April 29, 2027. The filing signals continued sponsor commitment without triggering early redemption or warranting amendment notices. No additional substance exists regarding customer claims, revenue metrics, market size, strategic initiatives, technology roadmaps, commercial partnerships, active litigation, or senior leadership changes beyond the routine CFO signature block.

What changed: Quarterly report (Form 10-Q) for the period ended September 30, 2025. The trust account dropped from ~$73.8M (Dec 31, 2024) to ~$18.7M (Sep 30, 2025) after the Third Extension Meeting on April 25, 2025, where holders of 4,776,757 public shares redeemed at ~$11.95/share for ~$57.1M. As of Sep 30, 2025, only 1,513,954 redeemable shares remained at $12.36 per share. Net loss for nine months was ~$14.4M driven by a $14.0M non-cash charge from the change in fair value of warrant liabilities and an $868,338 charge for the conversion option on the promissory notes. The outside date for the Sio Business Combination was extended to April 29, 2027 (fifth amendment, March 13, 2026), and a Fourth Extension Meeting on April 28, 2026 extended the liquidation deadline to April 29, 2027. At that meeting, 100,100 public shares redeemed at ~$12.93/share, leaving ~$18.3M in trust. Post-quarter end, the company drew $609,364 under the extension loan and $755,899 under the working capital loan. Sponsor has advanced $3,305,769 in total extension loans as of Sep 30, 2025. Why it matters: The trust is shrinking rapidly and the SPAC now has only 1.5M shares outstanding — a very small base — and an extended deadline to April 2027. The massive fair value swing on warrants and the new conversion option liability signal significant accounting volatility. The going concern footnote is explicit: management has "substantial doubt" about the company's ability to continue as a going concern. The fourth amendment to the Sio deal (Oct 2025) and fifth amendment (Mar 2026) show the target deal continues but hasn't closed; investors need to watch for further extensions or a deal failure.

What changed: Quarterly report on Form 10-Q for the period ended June 30, 2025, filed by Pyrophyte Acquisition Corp. (PHYT), a blank-check company searching for a business combination. Trust value dropped from $73.8M (Dec 2024) to $18.3M (Jun 2025) due to 4.78M share redemptions at ~$11.95 in the Third Extension (Apr 2025). Trust per share increased from $11.77 to $12.11. The liquidation deadline was extended from Apr 29, 2026 to Apr 29, 2027 via the Fourth Extension (Apr 28, 2026), with 100,100 additional redemptions at ~$12.93 leaving ~$18.3M in trust. The Sio business combination outside date was further extended to Apr 29, 2027 (fifth amendment Mar 13, 2026). Sponsor agreed to increase monthly extension deposits to $100,000 through Apr 2027. The company reported a net loss of $8.2M for 6 months (vs $2.0M net income in prior year), driven by $8.7M non-cash loss from warrant revaluation. The company disclosed a material weakness in internal controls and a going concern qualification. Why it matters: This filing provides updated trust value, per-share redemption price, and extension timeline critical for redemption decisions. It shows the sponsor continues to fund extensions, but the trust is shrinking and the deal with Sio remains unconsummated with multiple deadline extensions. The company's financial losses and control weaknesses raise risk. The trust per share has risen slightly, but the extended deadline to Apr 2027 gives more time for a deal.

What changed: Quarterly report (Form 10-Q) for Pyrophyte Acquisition Corp. for the three months ended March 31, 2025, including unaudited financial statements. As of March 31, 2025, the trust held $74,897,339 for 6,290,711 public shares, implying a redemption value of $11.91 per share (up from $11.77 at December 31, 2024). Net loss for the quarter was $3.19 million vs. net income of $1.94 million in prior year quarter, driven by a $3.64 million negative change in fair value of warrant liabilities. The sponsor advanced an additional $270,000 in extension contributions during the quarter. Subsequent to quarter end: (1) on April 25, 2025, 4,776,757 shares redeemed at ~$11.95, leaving ~$18.1 million in trust; (2) on April 28, 2026, a fourth extension to April 29, 2027 was approved with 100,100 additional shares redeemed at ~$12.93. The Sio Business Combination outside date was extended multiple times, now to April 29, 2027. Management expressed substantial doubt about the company's ability to continue as a going concern due to limited cash and the mandatory liquidation deadline. Why it matters: This filing confirms the trust's current per-share redemption value, the sponsor's continued funding of extensions, the ongoing erosion of trust assets through successive redemptions, and the company's reliance on multiple deadline extensions to consummate the Sio deal. The going concern warning and delisting to OTC Pink highlight elevated risk of liquidation if the business combination does not close before April 29, 2027.

What changed: SEC Form 12b-25 (Notification of Late Filing) submitting a request for an extension to file Pyrophyte Acquisition Corp.’s Quarterly Report on Form 10-Q for the period ended March 31, 2026. Why it matters: A pattern of missed SEC reporting cycles undermines investor oversight during the mandatory search phase, complicating independent validation of sponsor draw limits, operating expenses, and trust account integrity. The acknowledged potential for undisclosed accounting control weaknesses raises governance red flags that can pressure the board on timing for merger proposals, extension approvals, or liquidation triggers.

What changed: A Form 8-K current report (Item 8.01 Other Events) filed by Pyrophyte Acquisition Corp. documenting the results of an extraordinary general meeting, including a SPAC initial business combination extension, shareholder redemptions, revised trust account balances, and sponsor-funded maintenance deposits. According to the registrant’s Item 8.01 disclosure, shareholders approved at an extraordinary general meeting on April 28, 2026 an extension of the time to consummate an initial business combination from April 29, 2026 to April 29, 2027. Per the Company’s statement, holders of 100,100 Class A ordinary shares exercised redemption rights, resulting in approximately $1.29 million being removed from the Trust Account at approximately $12.93 per share. Following these redemptions, approximately $18.3 million remained in the Trust Account as of April 30, 2026. The registrant further states that post-redemption capitalization consists of 6,445,104 Class A Ordinary Shares outstanding, made up of 1,413,854 shares originally issued in the IPO and 5,031,250 shares originally issued to Pyrophyte Acquisition LLC as Class B ordinary shares. The filing also discloses that the Sponsor committed to depositing $100,000 monthly into the Trust Account through the Extension, and on May 4, 2026, the Sponsor caused the first month’s $100,000 deposit to be made. Beyond these structural changes, the document contains no claims about customers, revenue, market size, strategy, technology, partnerships, or litigation. It identifies the registrant as a Cayman Islands blank check company (SIC 6770) headquartered in Houston, Texas, with administrative execution attributed to Chief Financial Officer Sten Gustafson. Why it matters: This filing directly recalibrates the trust distribution floor and public share count ahead of the newly established April 29, 2027 deadline. Investors tracking redemption windows will note the $12.93 per-share payout and the $18.3 million residual trust balance, which defines the maximum recoverable amount if dissolution occurs before a deal closes. The reduction of 100,100 shares lowers the outstanding public float to 6,445,104 shares, altering relative voting weight and future dilution exposure. The contractual requirement for $100,000 monthly sponsor contributions extends the trust’s liquidity runway and financially commits the sponsor to preserving liquidation value throughout the extension, indicating active continuation of deal pursuit despite the complete absence of any target announcement, revenue projection, or operational milestone. All metrics, dates, and commitments are sourced exclusively from the registrant’s Item 8.01 report.

What changed: A Joint Filing Agreement (Exhibit A) accompanying a Schedule 13G beneficial ownership report. The document records only the procedural authorization by which eight affiliated parties—Harraden Circle Investments, LLC; Harraden Circle Investors GP, LP; Harraden Circle Investors GP, LLC; Harraden Circle Investors, LP; Harraden Circle Special Opportunities, LP; Harraden Circle Strategic Investments, LP; Harraden Circle Concentrated, LP; and Frederick V. Fortmiller, Jr.—consent to file a single Schedule 13G on behalf of each under Rule 13d-1(k). Dated April 30, 2026, and executed solely by Frederick V. Fortmiller, Jr. as Managing Member or authorized signatory, the excerpt provides zero data on aggregate share quantity, percentage of outstanding common stock, acquisition price, date of acquisition, or stated purpose of the purchase. Accordingly, no adjustment to redemption deadline calculations, trust-per-share distributions, extension balloting windows, combination vote scheduling, or sponsor governance conduct is triggered or disclosed by this text. Why it matters: Investors tracking SPAC mechanics receive no operational update from this page because the core Schedule 13G information sheet—which would normally specify whether the Harraden Circle complex crossed a reporting threshold, intends to acquire additional shares, or seeks board representation—is entirely absent. The bundling of multiple limited partnerships and their general partner into one joint filing reflects routine compliance administration rather than a tactical accumulation or activism move. With no claims regarding customer contracts, recurring revenue, addressable market size, strategic pivot, proprietary technology, partnership arrangements, active litigation, or executive appointments contained in the exhibit, the filing carries no direct weight on capital structure searches, target negotiation timelines, or shareholder liquidity events. Materiality remains low until the accompanying data schedule or purpose statement becomes publicly available.

What changed: A Form 8-K current report documenting a shareholder-approved trust account extension, the issuance of sponsor-directed promissory notes, and a temporary extension of the public share redemption reversal deadline. Per the filing by Pyrophyte Acquisition Corp., shareholders voted 6,366,583 For, 0 Against, and 0 Abstain to amend the Articles to extend the initial business combination deadline from April 29, 2026 to April 29, 2027. Concurrently, the Company increased mandatory monthly trust account loans from the Sponsor from the greater of $0.05 per public share or $75,000 to a flat $100,000 per calendar month beginning April 30, 2026. The filing grants existing redemption request holders a revised reversal window closing Friday, May 1, 2026 at 5:00 p.m. Eastern Time through transfer agent Continental Stock Transfer & Trust Company. Financial obligations were also updated: the Company issued a Fourth Extension Note to Sponsor Pyrophyte Acquisition LLC with a maximum principal of $1,200,000 bearing zero percent interest, repayable solely from non-trust funds upon liquidation or consummation. Additionally, the Working Capital Convertible Promissory Note was amended to extend its maturity to the Extended Date, raise its aggregate limit to $2,500,000, and grant the Sponsor an option to convert up to $1,500,000 into warrants at a $1.00 conversion price, with each warrant entitled to purchase one Class A ordinary share at $11.50 per share. Amendments to Article 51.7 and 51.8 clarify a ten-business-day post-deadline liquidation window and preserve 100 percent redemption triggers for future charter modifications. Why it matters: This filing confirms the Sponsor’s commitment to sustain operations for an additional twelve-month extension cycle using fully subordinated, trust-waived debt, indicating active pursuit of a target rather than imminent liquidation. The $100,000 monthly contribution rate directly offsets trust account erosion from ongoing corporate and administrative expenses, meaning the actual per-share trust value available at redemption will reflect cumulative monthly deductions over the additional year. The compressed May 1 reversal deadline establishes a discrete liquidity event for public investors before the new funding cycle commences. From a capital structure standpoint, the convertible note provision introduces conditional dilution: if the Sponsor elects to convert up to $1,500,000 prior to a business combination, it would inject warrants exercisable at $11.50 per share that carry identical rights to the original private placement warrants but escape their standard forfeiture clauses. The document contains no disclosures regarding target candidates, pipeline meetings, revenue projections, market sizing, operational strategy, or strategic rationale beyond routine governance amendments and financial accommodation terms.

What changed: A DEFA14A filing containing an 8-K current report (Item 8.01 Other Events) submitted by Pyrophyte Acquisition Corp. on April 22, 2026, serving as definitive additional materials disclosing trust account updates, extension payment confirmations, and proxy logistics ahead of a fourth shareholder meeting to extend the business combination deadline. The Company reports that as of April 22, 2026, the Trust Account holds approximately $19,545,779. The Company states there are currently 1,513,954 Class A ordinary shares eligible for redemption at the upcoming Fourth Extension EGM, and calculates that the implied liquidation value for those shares, if redeemed at that meeting, is approximately $12.91 per Public Share. The Company attributes to the Sponsor, Pyrophyte Acquisition LLC, a prior agreement to deposit $75,697.70 monthly through the Third Extension period (which was approved on April 25, 2025, extending the combination deadline to April 29, 2026), and states the Company has confirmed all such Extension Amounts were deposited. The Company further notes that an Extension Proxy Statement dated April 8, 2026 was mailed to shareholders of record as of March 27, 2026, approximately on April 9, 2026, to solicit votes for a fourth extension. Why it matters: This filing materially shifts the near-term redemption calendar by activating preparations for a Fourth Extension EGM and supplying the precise trust balance (~$19,545,779) and per-share liquidation metric (~$12.91) investors must weigh against the 1,513,954 outstanding public shares when deciding whether to redeem. By documenting that the sponsor funded the previous monthly extension installments at $75,697.70 per month, the filing confirms sponsor conduct and illustrates the cash infusions sustaining the trust pool ahead of the next deadline. No target acquisition, revenue figures, technology disclosures, or partnership announcements are contained in the text; instead, the document relies on standard forward-looking risk disclaimers and designates Chief Financial Officer Sten Gustafson as the contact for obtaining the definitive proxy statement. For investors tracking SPAC mechanics, the substance lies in the verified extension payment trail and the recalculated liquidation floor, which together dictate whether existing positions should be hedged, tendered, or maintained pending the outcome of the fourth extension vote.

What changed: An Item 8.01 'Other Events' Form 8-K current report issued by Pyrophyte Acquisition Corp. to notify the market that the sponsor has completed all required extension deposits, to disclose the updated trust account balance, to calculate the projected per-share liquidation value ahead of a shareholder redemption vote, and to direct investors to the definitive proxy statement governing a proposed fourth extension. According to the Company’s filing, signed by Chief Financial Officer Sten Gustafson on April 22, 2026, Pyrophyte Acquisition LLC has successfully deposited every monthly extension amount of $75,697.70 previously pledged for the Third Extension period, which extended the business combination deadline from April 29, 2025, to April 29, 2026. As of April 22, 2026, the Company states the Trust Account holds approximately $19,545,779. The filing identifies 1,513,954 Class A ordinary shares as currently eligible for redemption at the Fourth Extension EGM, and projects an implied liquidation value of approximately $12.91 per Public Share if redeemed at that meeting. The Company further advises that its definitive proxy statement dated April 8, 2026 was mailed to shareholders of record as of March 27, 2026, around April 9, 2026. Outside of these capital, extension, and proxy mechanics, the filing contains only standard forward-looking statement disclaimers, risk factor cross-references to the 2024 Form 10-K and the Extension Proxy Statement, participant solicitation disclosures, and a non-solicitation legal notice; it reports no target acquisition details, customer data, revenue projections, technology roadmaps, partnership agreements, pending litigation, or executive personnel changes. Why it matters: The document materially updates the redemption calendar by pinpointing the Fourth Extension EGM as the near-term catalyst where public shareholders can exercise redemption rights against the trust fund. By confirming the sponsor fully satisfied its $75,697.70 monthly payment schedule, the filing serves as a compliance checkpoint regarding sponsor capital contributions during the extension phase. For investors monitoring trust value and capital preservation, the reported $19,545,779 balance and the Company’s stated $12.91 per-share approximation establish the theoretical redemption floor tied to the upcoming vote, though the Company explicitly frames this figure as contingent on proper submission for redemption at the Fourth Extension EGM and subject to proxy approval. The mailing of the definitive proxy statement initiates the formal voting window, requiring holders to review the extension proposal, associated risks, and participant interests before the April 29, 2026, contractual deadline expires.